Epizyme (EPZM) Market Value Rose While Rock Springs Capital Management LP Cut Position by $850,000; Flow Traders Us Position in Credit Suisse Ag/Nassau (ZIV) Has Increased by $401,751

June 13, 2018 - By Ellis Scott

Epizyme, Inc. (NASDAQ:EPZM) Logo

Flow Traders Us Llc increased its stake in Credit Suisse Ag/Nassau (ZIV) by 37.05% based on its latest 2018Q1 regulatory filing with the SEC. Flow Traders Us Llc bought 6,377 shares as the company’s stock rose 2.84% while stock markets declined. The institutional investor held 23,589 shares of the investment bankers and brokers and service company at the end of 2018Q1, valued at $1.51M, up from 17,212 at the end of the previous reported quarter. Flow Traders Us Llc who had been investing in Credit Suisse Ag/Nassau for a number of months, seems to be bullish on the $132.72M market cap company. The stock decreased 0.06% or $0.05 during the last trading session, reaching $77.51. About 99,616 shares traded. VelocityShares Daily Inverse VIX MT ETN (NASDAQ:ZIV) has risen 16.65% since June 13, 2017 and is uptrending. It has outperformed by 4.08% the S&P500.




Rock Springs Capital Management Lp decreased its stake in Epizyme Inc (EPZM) by 3.77% based on its latest 2018Q1 regulatory filing with the SEC. Rock Springs Capital Management Lp sold 50,000 shares as the company’s stock rose 3.36% while stock markets declined. The hedge fund held 1.28 million shares of the health care company at the end of 2018Q1, valued at $22.63 million, down from 1.33 million at the end of the previous reported quarter. Rock Springs Capital Management Lp who had been investing in Epizyme Inc for a number of months, seems to be less bullish one the $1.09 billion market cap company. The stock decreased 2.18% or $0.35 during the last trading session, reaching $15.7. About 162,740 shares traded. Epizyme, Inc. (NASDAQ:EPZM) has risen 14.24% since June 13, 2017 and is uptrending. It has outperformed by 1.67% the S&P500. Some Historical EPZM News: 14/03/2018 – EPIZYME INC EPZM.O : WEDBUSH RAISES TARGET PRICE TO $24 FROM $21; RATING OUTPERFORM; 23/04/2018 – Epizyme: FDA Issued Partial Clinical Hold Affecting New Enrollment; 23/04/2018 – EPIZYME INC EPZM.O – PARTIAL CLINICAL HOLD WAS INITIATED FOLLOWING A SAFETY REPORT, SUBMITTED BY EPIZYME TO FDA AND OTHER REGULATORY AUTHORITIES; 23/04/2018 – Epizyme: U.S.-based Enrollment of New Patients Into Tazemetostat Studies Temporarily on Hold; 23/04/2018 – EPIZYME INC – U.S.-BASED ENROLLMENT OF NEW PATIENTS INTO TAZEMETOSTAT CLINICAL TRIALS IS TEMPORARILY ON HOLD; 13/03/2018 – Epizyme 4Q Loss $36.2M; 08/05/2018 – EPIZYME SAYS EU ORPHAN DESIGNATIONS RECEIVED FOR TAZEMETOSTAT; 08/05/2018 – Epizyme 1Q Rev $0.00; 16/03/2018 – New Research: Key Drivers of Growth for GDS HOLDINGS, Nova Measuring Instruments, Magic Software Enterprises, Epizyme, United C; 08/05/2018 – Epizyme 1Q Loss/Shr 49c

Another recent and important VelocityShares Daily Inverse VIX MT ETN (NASDAQ:ZIV) news was published by Seekingalpha.com which published an article titled: “Inverse Volatility Portfolio: Update After XIV Liquidation” on May 18, 2018.

Flow Traders Us Llc, which manages about $1.29 billion US Long portfolio, decreased its stake in Schwab International Equity Et (SCHF) by 1.56M shares to 115,783 shares, valued at $3.90 million in 2018Q1, according to the filing. It also reduced its holding in Barclays Bank Plc (JO) by 57,078 shares in the quarter, leaving it with 48,358 shares, and cut its stake in Ishares Russell 1000 Etf (IWB).

Rock Springs Capital Management Lp, which manages about $319.00M and $2.34B US Long portfolio, upped its stake in Biocryst Pharmaceuticals (NASDAQ:BCRX) by 112,500 shares to 925,000 shares, valued at $4.41 million in 2018Q1, according to the filing. It also increased its holding in Hologic Inc (NASDAQ:HOLX) by 65,000 shares in the quarter, for a total of 400,000 shares, and has risen its stake in Celgene Corp (NASDAQ:CELG).

Since February 5, 2018, it had 0 buys, and 1 sale for $1.20 million activity.

Investors sentiment increased to 1.5 in Q1 2018. Its up 0.29, from 1.21 in 2017Q4. It increased, as 13 investors sold EPZM shares while 25 reduced holdings. 22 funds opened positions while 35 raised stakes. 57.44 million shares or 0.90% more from 56.93 million shares in 2017Q4 were reported. Northern Tru Corporation, a Illinois-based fund reported 580,898 shares. American Group Inc Inc has 31,313 shares for 0% of their portfolio. California Employees Retirement reported 135,500 shares. Oracle Inv Mgmt invested in 396,325 shares. Walleye Trading Ltd Liability Corporation, a Minnesota-based fund reported 10,471 shares. Nea has 6.46 million shares for 5.1% of their portfolio. Geode Capital Mgmt Ltd Com invested in 477,843 shares. Marshall Wace Ltd Liability Partnership invested in 64,651 shares. 4,180 were accumulated by Ameritas Inv Inc. Alliancebernstein Limited Partnership stated it has 0% in Epizyme, Inc. (NASDAQ:EPZM). Royal Financial Bank Of Canada holds 0% or 880 shares. Franklin holds 0.01% of its portfolio in Epizyme, Inc. (NASDAQ:EPZM) for 960,200 shares. Bank Of America Corp De holds 54,714 shares. State Of Wisconsin Inv Board reported 49,300 shares or 0% of all its holdings. Legal General Gru Public Limited Liability holds 0% of its portfolio in Epizyme, Inc. (NASDAQ:EPZM) for 9,483 shares.

Analysts await Epizyme, Inc. (NASDAQ:EPZM) to report earnings on August, 3. They expect $-0.53 EPS, down 10.42% or $0.05 from last year’s $-0.48 per share. After $-0.49 actual EPS reported by Epizyme, Inc. for the previous quarter, Wall Street now forecasts 8.16% negative EPS growth.

More notable recent Epizyme, Inc. (NASDAQ:EPZM) news were published by: Nasdaq.com which released: “Report: Developing Opportunities within Silicon Motion Technology, Green Brick Partners, Alliance Resource Partners …” on June 06, 2018, also Streetinsider.com with their article: “Epizyme (EPZM) to Present New Tazemetostat Data at ASCO and EHA” published on May 17, 2018, Nasdaq.com published: “Epizyme to Host Investor Conference Call to Discuss Interim Follicular Lymphoma Clinical Data” on June 01, 2018. More interesting news about Epizyme, Inc. (NASDAQ:EPZM) were released by: Nasdaq.com and their article: “Epizyme Presents Encouraging Phase 2 Data of Tazemetostat for Malignant Mesothelioma at ASCO” published on June 03, 2018 as well as Streetinsider.com‘s news article titled: “Epizyme (EPZM) Phase 2 Data of Tazemetostat for Malignant Mesothelioma Met Primary Endpoint” with publication date: June 04, 2018.

Epizyme, Inc. (NASDAQ:EPZM) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: